Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib.

CONCLUSIONS: Higher BTK occupancy was achieved with twice daily over once daily dosing, resulting in deeper and more sustained inhibition of BCR signaling.
PMID: 32054731 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 12, 2020 Category: Cancer & Oncology Authors: Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierman P, Hamdy A, Izumi R, Bibikova E, Patel P, Sun C, Covey T, Herman SEM, Wiestner A Tags: Clin Cancer Res Source Type: research